Abstract library

1191 results for "locoregional treatment".
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#1269 CEA Level, Radical Surgery and CD56 Expression Are Prognostic Factors for Patients with Locoregional Gastrin-independent GNET
Introduction: Gastrin-independent gastric neuroendocrine tumors (GNETs) are highly malignant. Radical resections and lymphadenectomy are considered to be the only possible curative treatment for these tumors. However, the prognosis of gastrin-independent GNETs is not well defined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Yuan Li
Authors: Li Y, Zhao H, Cai J, ...
#528 Trans-Arterial Embolization (TAE) is the Best Locoregional Treatment Option for Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Trans-arterial embolization (TAE) and chemoembolization (TACE) have been shown to be effective in patients (pts) with liver metastases (LM) from gastroenteropancreatic neuroendocrine tumor (GEP NET). TAE and TACE goal is to reduce blood flow to the tumor resulting in ischemia and necrosi.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Michela Del Prete
Keywords: TAE, TACE, NET
#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment
#393 Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions
Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Esther I. Van Vliet
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...